 |
The results show that these common drugs are linked to lower prevalence of AMD in European populations.
AMD is the leading cause of severe visual impairment among older people in high-income countries. In Europe alone, 67 million people currently have the condition, with new cases projected to soar over the next few decades as populations age.
AMD affects central vision and the ability to see fine detail. Various genetic and environmental factors associated with aging are thought to trigger AMD, but it’s still not clear how best to prevent it or slow its progression.
Previously published research suggests that drugs to lower cholesterol, control diabetes, and dampen down inflammation may help to lessen the risk of developing AMD, but these findings were partly contradictory and based on small numbers of participants.
In a bid to get round these issues, the researchers pooled the results of 14 population-based and hospital-based studies, involving 38,694 people from France, Germany, Greece, Ireland, Italy, Norway, Portugal, Russia and the UK.
The studies were part of the European Eye Epidemiology (E3) consortium, a collaborative pan European network, the principal aim of which is to develop and analyze large pooled datasets to further the understanding of eye disease and sight loss.
Participants were all over the age of 50 and taking at least one of the following types of drug to: lower cholesterol, including statins; control diabetes, including insulin; to dampen down inflammation, excluding steroids; and Levodopa, used to treat movement disorders caused by neurodegenerative disease.
Since you’re here...we have a small favor to ask. Retina Global is a nonprofit, and we have to depend on your support to sustain the work we do. Hence the need to ask for your help. Retina Global's work is important, since it not only provides help to disadvantaged people, but also provides resources for developing new treatments that can potentially cure blindness. What we do takes a lot of time, money and hard work. But we do it because we believe we have to help stop someone somewhere from going blind. So make a difference. Click here to donate. Your support is much appreciated. Thank you!
The prevalence of AMD ranged from 12% to 64.5% across the included studies—9332 cases in total—while the prevalence of advanced (late) AMD ranged from 0.5% to 35.5%—951 cases in total.
The pooled data analysis showed that drugs to lower cholesterol or control diabetes were associated with, respectively, 15% and 22% lower prevalence of any type of AMD, after accounting for potentially influential factors.
No such associations were found for any of the other types of drug or for advanced AMD, in particular, although there were only a relatively small number of such cases, note the researchers.
Theirs is the first large pooled data analysis of its kind to use individual level data from various population-based and hospital-based studies, highlight the researchers.
The findings point to a likely key role for metabolic processes in the development of AMD, which may offer potential new avenues for treatment and have implications for public health messaging, they suggest.
Lightly edited from the Source.
Picture (c) Image Bank, ASRS
More about Retina Global here. We seek your support. Click here to donate.
No comments:
Post a Comment
Thanks for your comments. We will get back to you shortly if there is a need to respond to it.
- Admin, Retina Global
Read more on Retina Global.